Rezafungin
Kathryn Dzintars, Pharm.D., BCPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Treatment of candidemia or invasive candidiasis in adults (≥18) with limited or no alternative options for candidemia/invasive candidiasis.
- Approval was based on limited clinical safety and efficacy data.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Rezafungin is currently being investigated for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.